Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...
“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza ...
Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.
A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
The aTIV vaccine provides better protection against influenza-related medical encounters than the HD-TIV vaccine in high-risk older adults.
This broad-spectrum influenza vaccine candidate is being evaluated as a booster for participants who received OVX836 three to five years ago. The trial is being conducted at the Center for ...
The study is taking place at the Center for Vaccinology (CEVAC) at Ghent University Hospital. OVX836 is a first-in-class influenza A vaccine candidate that targets the nucleoprotein (NP), a highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback